Partnership deals that involve drugs in pipeline stage have shown a gradual increase of 8% for the US over the last 5 years. The US still remains to dominate the market, however partnership deals with drugs in pipeline stage for China has also shown a significant increase of 5% from 2013 to 2017.

Figure 1 shows the % of Partnership Deals with Pipeline Drugs for the US compared to the BRICS* countries over the last 5 years. The BRICS* countries continue to own a third of the global share of these deals where China and Brazil combined have more than half of the BRICS countries partnership deals in addition to showing the most % increase over time.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

China tend to prefer partnership strategic alliance deals as they can share resources at an affordable cost instead of the higher risks and increased regulations required with acquisitions.